Galmed Pharma (GLMD) Tops Q3 EPS by 3c

Galmed Pharma (NASDAQ: GLMD) reported Q3 EPS of ($0.23), $0.03 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $300 thousand versus the consensus estimate of $330 thousand.

For earnings history and earnings-related data on Galmed Pharma (GLMD) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Fabrinet (FN) Tops Q4 EPS by 29c, Beats on Revenue; Offers Guidance
• Home Depot beats estimates, reaffirms fiscal 2026 guidance